Updates

  1. TheSocialMedwork commitment during the COVID-19 outbreak

    Here some frequently asked questions and answers that touch on important COVID-19 related updates.

    Lee mas »
  2. Promising new data analysis for Alzheimer’s disease treatment

    New analysis of Biogen’s aducanumab shows reduction in clinical decline in Alzheimer’s disease.

    Xray of human brain

    Lee mas »
  3. MN-166 (ibudilast) to enter phase III clinical trials for progressive MS

    MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

    pipette samples

    Lee mas »
  4. Phase 2 study: Ibudilast's effects in progressive MS

    Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

    red mri brain scan

    Lee mas »
  5. New cancer medicine targets tumour biomarkers anywhere in the body

    The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

    US flag thumbs up gesture

    Lee mas »
  6. Lung cancer medicine receives positive opinion in the EU

    CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

    EU approval OK hand gesture

    Lee mas »
  7. Cancer medicine, Lartruvo (olaratumab), does not prolong life

    After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

    old bench

    Lee mas »
  8. Truxima (rituximab) gains FDA approval as the first biosimilar for Non-Hodgkin's Lymphoma

    A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

    approved stamp with stars

    Lee mas »
  9. Vyndaqel (tafamidis) prolongs life of FAP patients

    Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

    grandfather pointing into sea

    Lee mas »
  10. A new gene therapy on the horizon for SMA

    Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

    baby outside reaching toward viewer

    Lee mas »
Posts loader